Our top pick for
Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
Agios Pharmaceuticals Inc is a biotechnology business based in the US. Agios Pharmaceuticals shares (AGIO) are listed on the NASDAQ and all prices are listed in US Dollars. Agios Pharmaceuticals employs 562 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$44.28|
|52-week range||$32.47 - $62.16|
|50-day moving average||$45.76|
|200-day moving average||$51.51|
|Wall St. target price||$62.43|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$23.67|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-08)||N/A|
|1 month (2021-09-17)||-6.07%|
|3 months (2021-07-19)||-21.38%|
|6 months (2021-04-19)||-18.77%|
|1 year (2020-10-19)||25.51%|
|2 years (2019-10-18)||33.90%|
|3 years (2018-10-19)||66.88|
|5 years (2016-10-19)||48.32|
Valuing Agios Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Agios Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Agios Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 2x. In other words, Agios Pharmaceuticals shares trade at around 2x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
|Revenue TTM||$203.2 million|
|Gross profit TTM||$-167,079,000|
|Return on assets TTM||-14.4%|
|Return on equity TTM||-29.42%|
|Market capitalisation||$2.7 billion|
TTM: trailing 12 months
There are currently 6.2 million Agios Pharmaceuticals shares held short by investors – that's known as Agios Pharmaceuticals's "short interest". This figure is 8.6% up from 5.7 million last month.
There are a few different ways that this level of interest in shorting Agios Pharmaceuticals shares can be evaluated.
Agios Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Agios Pharmaceuticals shares currently shorted divided by the average quantity of Agios Pharmaceuticals shares traded daily (recently around 411083.52084712). Agios Pharmaceuticals's SIR currently stands at 15.11. In other words for every 100,000 Agios Pharmaceuticals shares traded daily on the market, roughly 15110 shares are currently held short.
However Agios Pharmaceuticals's short interest can also be evaluated against the total number of Agios Pharmaceuticals shares, or, against the total number of tradable Agios Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Agios Pharmaceuticals's short interest could be expressed as 0.11% of the outstanding shares (for every 100,000 Agios Pharmaceuticals shares in existence, roughly 110 shares are currently held short) or 0.1066% of the tradable shares (for every 100,000 tradable Agios Pharmaceuticals shares, roughly 107 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Agios Pharmaceuticals.
Find out more about how you can short Agios Pharmaceuticals stock.
We're not expecting Agios Pharmaceuticals to pay a dividend over the next 12 months.
Over the last 12 months, Agios Pharmaceuticals's shares have ranged in value from as little as $32.47 up to $62.16. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Agios Pharmaceuticals's is 1.5624. This would suggest that Agios Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Agios Pharmaceuticals, Inc. , a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers TIBSOVO (ivosidenib), an oral targeted inhibitor for treating adult patients with relapsed or refractory acute myeloid leukemia (R/R AML), as well as to treat patients with newly diagnosed AML; and IDHIFA (enasidenib), an oral targeted inhibitor for patients with R/R AML and an isocitrate dehydrogenase 2 mutation. It is also developing TIBSOVO, which has completed Phase II clinical trials to treat IC eligible frontline AML; that is in Phase III clinical trials for treating IC ineligible frontline AML; and that is in Phase III clinical trials for the treatment of cholangiocarcinoma, as well as in early stage clinical development to treat glioma and solid tumors. In addition, the company is developing IDHIFA, which has completed Phase II clinical study for treating IC eligible frontline AML; and that is in Phase I/II clinical trials for the treatment of IC ineligible frontline AML. Further, it is developing mitapivat, which is in Phase III clinical trials to treat pyruvate kinase deficiency, as well as in Phase II clinical study for treating thalassemia and sickle cell disease; vorasidenib (AG-881) that is in Phase I clinical trials for the treatment of solid tumors, including glioma; AG-270, which is in Phase I dose-escalation trial to treat methylthioadenosine phosphorylase deleted tumors; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc.
Everything we know about the Aura Biosciences IPO, plus information on how to buy in.
Everything we know about the Claros Mortgage Trust IPO, plus information on how to buy in.
Everything we know about the Evotec SE IPO, plus information on how to buy in.
Everything we know about the Delimobil Holding SA IPO, plus information on how to buy in.
Everything we know about the Blue Water Vaccines IPO, plus information on how to buy in.
Everything we know about the Sonendo IPO, plus information on how to buy in.
Everything we know about the FlexEnergy Green Solutions IPO, plus information on how to buy in.
Everything we know about the Stran & Company IPO, plus information on how to buy in.
Everything we know about the Kidpik Corp IPO, plus information on how to buy in.
Everything we know about the Nuvectis Pharma IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.